

Supplementary Table 2: Characteristics of RCDII patients according to *JAK1* and *STAT3* status

	Total (N=50)	<i>JAK1</i>			<i>STAT3</i>		
		Mutated (N=24)	Not mutated (N=26)	Stat	Mutated (N=19)	Not mutated (N=31)	Stat
Clinical features							
Age, mean in years (range)	57 (29-77)	57 (30-77)	57 (29-77)	ns	54 (37-71)	59 (29-77)	ns
Gender (F, %)	32 (64%)	13 (54%)	19 (73%)	ns	16 (84%)	16 (52%)	p=0.03
Time from CeD diagnosis to molecular evaluation, mean in years (range)	5.4 (0.1-21.9)	5.3 (2.7-17.9)	5.4 (0.1-21.9)	ns	4.5 (0.1-10.9)	5.9 (0.2-21.9)	ns
Develops EATL (%)	16 (32%)	8 (33%)	8 (31%)	ns	6 (32%)	10 (32%)	ns
Biological features							
Flow cytometry (N=), small bowel biopsies	33	15	18		14	19	
% aberrant population in IEL (/CD45 ⁺)	72% (23-98)	80% (46-98)	65% (23-89)	p=0.04	71% (23-95)	73% (30-98)	ns
% aberrant population in LPL (/CD45 ⁺)	32% (5-70)	43% (6-94)	23% (5-70)	p=0.03	30% (6-60)	34% (5-70)	ns
% aberrant population in PBL (/CD45 ^{hi})	7% (0-80)	12% (0-80)	3% (0-11)	ns	11% (0-80)	4% (0-25)	ns
TCR status (frozen biopsies)							
Gamma clonal	48 (96%) [#]	23 (96%) [#]	25 (96%) [#]	ns	19 (100%)	29 (94%) [#]	ns
VDJ Beta clonal	15/49 (31%)	9/23 (39%)	6/26 (23%)	ns	6/19 (32%)	9/30 (30%)	ns
Mutational status (frozen biopsies)							
<i>JAK1</i> mutations	24 (48%)	-	-		5 (26%)	19 (61%)	p=0.02
<i>STAT3</i> mutations	19 (38%)	5 (21%)	14 (54%)	p=0.02	-	-	-
<i>TNFAIP3/TNIP3</i> mutations	10/47 (21%)	4/21 (19%)	6 (23%)	ns	7/19 (37%)	3/28 (11%)	p=0.07
<i>DDX3X</i> mutations	10/50 (20%)	4 (21%)	6 (23%)	-	4 (21%)	6 (19%)	ns

[#] two cases with polyclonal TCR γ and clonal TCR δ